EverSource Wealth Advisors LLC Sells 91 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

EverSource Wealth Advisors LLC lessened its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 11.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 673 shares of the medical equipment provider’s stock after selling 91 shares during the period. EverSource Wealth Advisors LLC’s holdings in Zimmer Biomet were worth $82,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. PFG Advisors boosted its stake in shares of Zimmer Biomet by 4.6% in the 4th quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider’s stock valued at $231,000 after purchasing an additional 84 shares in the last quarter. Quent Capital LLC grew its stake in shares of Zimmer Biomet by 21.6% during the fourth quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after buying an additional 92 shares during the last quarter. Stokes Family Office LLC increased its holdings in shares of Zimmer Biomet by 4.1% during the third quarter. Stokes Family Office LLC now owns 2,498 shares of the medical equipment provider’s stock worth $280,000 after buying an additional 99 shares in the last quarter. Parkside Financial Bank & Trust lifted its stake in shares of Zimmer Biomet by 15.6% in the 3rd quarter. Parkside Financial Bank & Trust now owns 756 shares of the medical equipment provider’s stock valued at $85,000 after acquiring an additional 102 shares during the last quarter. Finally, Bridge Creek Capital Management LLC boosted its holdings in shares of Zimmer Biomet by 0.4% during the 4th quarter. Bridge Creek Capital Management LLC now owns 24,895 shares of the medical equipment provider’s stock valued at $3,030,000 after acquiring an additional 107 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Trading Up 0.5 %

Shares of ZBH stock opened at $116.41 on Monday. The company has a market cap of $23.95 billion, a P/E ratio of 25.20, a PEG ratio of 2.10 and a beta of 1.03. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $147.50. The stock has a 50 day simple moving average of $123.45 and a two-hundred day simple moving average of $121.73. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.07. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. Zimmer Biomet’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.89 EPS. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Wednesday, June 26th will be paid a $0.24 dividend. The ex-dividend date is Wednesday, June 26th. This represents a $0.96 annualized dividend and a dividend yield of 0.82%. Zimmer Biomet’s dividend payout ratio is presently 20.78%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Citigroup lifted their price target on Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Barclays upped their price target on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research report on Monday, February 12th. JPMorgan Chase & Co. lifted their price target on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a report on Friday, February 9th. TheStreet raised shares of Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. Finally, Oppenheimer raised their target price on Zimmer Biomet from $150.00 to $155.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $134.40.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.